01.06.21 X4 Pharma Adjusts Clinical Trials For A COVID-19 World
The goal of this report is to help readers stay on top of trends such as the use of challenge trials, diagnostic development, and how companies are responding to the COVID-19 pandemic. Over 130 Phase 1 decision-makers were surveyed to share insights into where the Phase 1 market is now and what changes they expect over the next four years. Click here to learn more.
Featured Editorial
By Ed Miseta, chief editor, Clinical Leader
With the COVID-19 pandemic afflicting patients around the world, those with a compromised immune system are at even greater risk. X4 Pharma is currently conducting a global Phase 3 trial that was already underway when the pandemic hit and concerns patients who are immunocompromised.